ArticleJournal of clinical laboratory analysis2026
Time- and Temperature-Dependent Response of Acquired FV Inhibitors: Implications for Laboratory Diagnosis and Clinical Management.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcquired factor V (FV) inhibitors are rare circulating autoantibodies that may cause severe bleeding and false-negative detection without standardized incubation. This study aimed to evaluate time- and temperature-dependent FV inhibitor activity and define optimal laboratory detection conditions.
methodsFifteen serially diluted plasma samples from 4 FV inhibitor-positive patients were incubated at room temperature (RT) or 37°C for 0-120 min. APTT mixing assays, residual FV activity, PT mixing assays, and Bethesda inhibitor titers were detected, with inhibitor-free normal pooled plasma (NPP) as thermal degradation control. ISTH-recommended MTC index was adopted for standardized mixing result interpretation.
resultsAt 37°C, APTT/PT mixing times were progressively prolonged and residual FV activity declined continuously, reaching a plateau at 60 min, whereas only slight changes occurred at RT. After excluding ~6% spontaneous FV thermal loss in NPP, residual FV activity at 37°C was significantly lower than RT at all time points (p < 0.05). Bethesda titers rose progressively at 37°C across all samples, confirming antibody-mediated neutralization rather than native protein decay. Pronounced inter‑individual variability in inhibitor potency was observed under equalized inhibitor concentrations.
conclusionsFV inhibitors exhibit distinct time- and temperature-dependent neutralizing activity. RT testing without sufficient 37°C incubation raises false-negative risk. Universal 2 h incubation at 37°C is recommended for routine inhibitor screening; 60 min incubation is only suitable for follow-up of confirmed FV inhibitor cases and cannot replace standard 2-h protocol for ruling out FVIII inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.